Correlation Between Bristol Myers and AstraZeneca PLC

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and AstraZeneca PLC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and AstraZeneca PLC into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and AstraZeneca PLC ADR, you can compare the effects of market volatilities on Bristol Myers and AstraZeneca PLC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of AstraZeneca PLC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and AstraZeneca PLC.

Diversification Opportunities for Bristol Myers and AstraZeneca PLC

0.15

Correlation Coefficient

Bristol Myers  AstraZeneca PLC

Average diversification

The 3 months correlation between Bristol and AstraZeneca is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and AstraZeneca PLC ADR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AstraZeneca PLC ADR and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with AstraZeneca PLC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AstraZeneca PLC ADR has no effect on the direction of Bristol Myers i.e., Bristol Myers and AstraZeneca PLC go up and down completely randomly.

Pair Corralation between Bristol Myers and AstraZeneca PLC

Considering the 90-day investment horizon Bristol Myers Squibb is expected to under-perform the AstraZeneca PLC. In addition to that, Bristol Myers is 1.45 times more volatile than AstraZeneca PLC ADR. It trades about -0.31 of its total potential returns per unit of risk. AstraZeneca PLC ADR is currently generating about 0.39 per unit of volatility. If you would invest  6,633  in AstraZeneca PLC ADR on January 26, 2024 and sell it today you would earn a total of  870.00  from holding AstraZeneca PLC ADR or generate 13.12% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  AstraZeneca PLC ADR

Bristol Myers Squibb

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Bristol Myers is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

AstraZeneca PLC ADR

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC ADR are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, AstraZeneca PLC may actually be approaching a critical reversion point that can send shares even higher in May 2024.

Pair Trading with Bristol Myers and AstraZeneca PLC

The main advantage of trading using opposite Bristol Myers and AstraZeneca PLC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, AstraZeneca PLC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will offset losses from the drop in AstraZeneca PLC's long position.

The idea behind Bristol Myers Squibb and AstraZeneca PLC ADR pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.